Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed stock last closed at $27.96, up 1.41% from the previous day, and has increased 50.08% in one year. It has overperformed other stocks in the Biotechnology industry by 0.75 percentage points. Insmed stock is currently +74.31% from its 52-week low of $16.04, and -1.27% from its 52-week high of $28.32.
As of Dec 8, 2023, there are 143.06M shares of INSM outstanding. The market cap of INSM is $4.00B. In the past 24 hours, 1.88M INSM shares were traded.
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
Based on our experience, eToro is the best brokerage. Here's why:
Get $10 towards your purchase of stock by signing up for an account with eToro today.Open eToro Account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
Now that you have filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your brokerage account.
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on INSM's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge INSM's fair value.
You can access additional valuation research on INSM's stock here.
Out of 7 sell side analysts who track INSM, the consensus analyst rating on Insmed is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Vamil Divan, a top 6% analyst from Guggenheim reiterates INSM with a strong buy rating and raises their INSM price target from $50.00 to $52.00, on Sep 5, 2023.
Guggenheim's Vamil Divan raised their price target on Insmed (NASDAQ: INSM) by 4% from $50 to $52 on 2023/09/05. The analyst reiterated their Strong Buy rating on the stock.
Following the favorable results of the "Phase 3 ARISE study of ARIKAYCE* in patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM)** lung infection caused by Mycobacterium avium complex (MAC)** who had not started antibiotics," Divan increased their price target.
Although Guggenheim anticipated an optimistic outcome, actual results are even more polished and compelling, the analyst noted.
* From here: ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function.
** From here: Nontuberculous mycobacteria (NTM) are mycobacteria which do not cause tuberculosis or leprosy (also known as Hansen's disease).
*** From here: Mycobacterium avium complex (MAC) lung disease is a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen over time, including chronic cough, dyspnea, fatigue, fever, weight loss, and chest pain.
Matthew Harrison, a bottom 4% analyst from Morgan Stanley reiterates INSM with a strong buy rating and maintains their INSM price target from $41.00 to $41.00, on Aug 4, 2023.
You can dig deeper into what analysts are saying on the Insmed stock forecast page.
Last year, INSM revenue was $280.82M. In the last four year, INSM's revenue has grown by 29.26% per year. This was slower than the Biotechnology industry average of 37.17%.
Dig into INSM's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at INSM have bought more shares than they have sold.
William Lewis, Chair and CEO of INSM, was the latest INSM insider to sell. They sold $33,155.76 worth of INSM shares on Oct 27, 2023.
Get more info about who owns INSM stock here.
No, Insmed doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
There are two primary types of orders:
Hit the Open button and eToro will execute your order.
If you want more info about buying stocks on eToro, watch the how to video below:
Now that you own some shares in INSM, you'll want to keep up with your new investment.
Start a watchlist to get notified of important updates regarding your INSM stock.
To summarize, here are the 6 steps you need to take to buy Insmed stock right now:
If you are looking for a brokerage account, eToro is our recommended option.Get Started with eToro Today
If you would like to keep tabs on your new investment in Insmed, get started below.
How much does it cost to buy one Insmed share?
Is now a good time to buy Insmed stock?
What is the best way to buy Insmed stock?